| P50 | author | Carlo Riccardo Rossi | Q40058555 |
| P2093 | author name string | Lise M | |
| | Alessio S | |
| | Foletto M | |
| | Vecchiato A | |
| | Menin N | |
| P2860 | cites work | The orderly progression of melanoma nodal metastases | Q72871409 |
| | Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit | Q78368402 |
| | En bloc resection of primary melanoma with regional lymph node dissection | Q82976675 |
| | Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma | Q24540048 |
| | Human tumor antigens recognized by T lymphocytes | Q24678508 |
| | Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients | Q30466404 |
| | Germline p16 mutations in familial melanoma | Q34059915 |
| | Speculations on the Role of Ultraviolet Radiation in the Development of Malignant Melanoma4 | Q34169631 |
| | Melanoma and use of sunscreens: an Eortc case-control study in Germany, Belgium and France. The EORTC Melanoma Cooperative Group | Q34313786 |
| | Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. | Q34371245 |
| | Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients | Q34619348 |
| | Model predicting survival in stage I melanoma based on tumor progression | Q34669608 |
| | Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. | Q34685253 |
| | A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma | Q34710725 |
| | Hyperthermic antiblastic perfusion in the treatment of local recurrence or "in-transit" metastases of limb melanoma | Q35532119 |
| | Melanoma and sun exposure: contrasts between intermittent and chronic exposure | Q35993013 |
| | Trends in mortality rates from malignant melanoma in Sweden 1953-1987 and forecasts up to 2007 | Q35994442 |
| | Autologous bone marrow transplantation and melanoma: a focused review of the literature. | Q36372890 |
| | Judging prognosis in malignant melanoma of the skin. A problem of inference over small data sets | Q36634717 |
| | Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer | Q37467673 |
| | Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease | Q38534866 |
| | The role of elective lymph node dissection in melanoma: rationale, results, and controversies | Q39625646 |
| | Spitz naevi and malignant melanomas of childhood and adolescence | Q39803344 |
| | Malignant melanomaa review of 10 years experience in Glasgow, Scotland | Q40066621 |
| | Prognostic value of lymph node dissection in malignant melanoma | Q40361763 |
| | Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer? | Q40559253 |
| | Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group | Q40748754 |
| | Recent developments in melanoma epidemiology, 1993. | Q40860314 |
| | Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines | Q40949071 |
| | Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma | Q41523597 |
| | Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions | Q42279980 |
| | In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions | Q42524093 |
| | In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma | Q42524096 |
| | The reliability of frozen sections in the evaluation of surgical margins for melanoma | Q43452556 |
| | Comparison of lymphedema following incontinuity and discontinuity groin dissection | Q43723098 |
| | The prognostic significance of ulceration of cutaneous melanoma | Q44362550 |
| | Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion | Q44550838 |
| | Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22 | Q44552643 |
| | A reversal in the long-term increase in deaths attributable to malignant melanoma | Q44705603 |
| | Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas | Q44966035 |
| | S-100 protein: is it useful as a tumour marker in diagnostic immunocytochemistry? | Q46534040 |
| | Chemosurgery for melanoma | Q46861759 |
| | Loco-regional nodal relapse in melanoma | Q46864744 |
| | S-100 protein as a marker for melanocytic and other tumours | Q48503550 |
| | Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. | Q50759657 |
| | The histological variance of malignant melanoma: the interrelationship of histological subtype, neoplastic progression, and biological behaviour. | Q50916588 |
| | Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. | Q50932915 |
| | Inefficacy of immediate node dissection in stage 1 melanoma of the limbs | Q50986397 |
| | Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). | Q52619561 |
| | Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. | Q52730145 |
| | A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. | Q52735595 |
| | A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. | Q52875002 |
| | Regional distribution of common and dysplastic naevi in relation to melanoma site and sun exposure. A case-control study | Q53494003 |
| | Early Recognition of Cutaneous Melanoma | Q54114512 |
| | Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: An eortc multicenter case-control study in Belgium, France and Germany | Q57415193 |
| | Recreational exposure to sunlight and lack of information as risk factors for cutaneous malignant melanoma. Results of an European Organization for Research and Treatment of Cancer (EORTC) case-control study in Belgium, France and Germany. The EORTC | Q57415196 |
| | The impact of ultrasound scanning in the staging and follow-up of patients with clinical stage i cutaneous melanoma | Q62711484 |
| | Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma | Q62711497 |
| | Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma | Q67294916 |
| | A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma.Preliminary results | Q67316111 |
| | Prognostic index in malignant melanoma | Q67349831 |
| | Malignant melanoma. Role of node dissection reappraised | Q67434632 |
| | Surgical management of primary melanoma | Q67584635 |
| | Closing in on melanoma susceptibility gene(s) | Q67584894 |
| | Cytogenetic analysis of melanocytes from premalignant nevi and melanomas | Q67924901 |
| | Technical details of intraoperative lymphatic mapping for early stage melanoma | Q68089035 |
| | Selective heat sensitivity of cancer cells. Biochemical and clinical studies | Q68568445 |
| | Thin malignant melanomas with regression and metastases | Q69415764 |
| | The biologic forms of malignant melanoma | Q69490079 |
| | Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study | Q69580503 |
| | Early detection of primary cutaneous malignant melanoma. A color atlas | Q69590282 |
| | Prognostic factors in patients with regional cervical nodal metastases from cutaneous malignant melanoma | Q69634167 |
| | Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases | Q69716711 |
| | Versatility and safety of flap coverage for wide excision of cutaneous melanomas | Q69901857 |
| | Levamisole as adjuvant therapy for melanoma: quo vadis? | Q70139441 |
| | Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma | Q70179818 |
| | Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial | Q70199408 |
| | Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors | Q70221797 |
| | Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions | Q70269701 |
| | Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study | Q70313321 |
| | Results of ilioinguinal dissection for stage II melanoma | Q70391886 |
| | Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion | Q70486255 |
| | Management of malignant melanoma of the head and neck | Q70486260 |
| | An aid to the preoperative assessment of pigmented lesions of the skin | Q70580290 |
| | Limited or selective nodal dissection for malignant melanoma of the head and neck | Q70636485 |
| | A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II) | Q70717837 |
| | Biopsy and prognosis for cutaneous malignant melanomas in clinical stage I | Q70742624 |
| | Cohort analysis of malignant melanoma in five countries | Q71000130 |
| | Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study | Q71093036 |
| | Low- and high-risk malignant melanoma--I. Evaluation of clinical and histological prognosticators in 585 cases | Q71228203 |
| | Low- and high-risk malignant melanoma--II. Multivariate analyses for a prognostic classification | Q71228206 |
| | Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients | Q71703423 |
| | Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma | Q71758295 |
| | Malignant melanoma of the skin. I. The association of tumor depth and type, and patient sex, age, and site with survival | Q71821368 |
| | Metastases in malignant melanoma | Q72039948 |
| | Clinical diagnosis of malignant melanoma | Q72114105 |
| | Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside | Q72377535 |
| | Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan | Q72736776 |
| | HLA-DQB1*0301 association with increased cutaneous melanoma risk | Q72804257 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2302-2312 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Management of cutaneous melanoma M0: state of the art and trends | |
| P478 | volume | 33 | |